Hormone receptor positive breast cancer+3
Not yet recruitingAbemaciclib plus drug combination in women with early-stage hormone‑positive HER2‑negative breast cancer: phase II study to reduce chemotherapy and surgery
Abemaciclib plus drug combination in women with early-stage hormone‑positive HER2‑negative breast cancer: phase II study to reduce chemotherapy and surgery
- Disease:Hormone receptor positive breast cancerBreast cancer stage III+2
- Substances:AbemaciclibAnastrozole+6
Italy- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
- Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri










